The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: A meta-analysis of studies from recent decade (2008-2018)

被引:39
作者
Pan, Bo [1 ,2 ]
Xu, Ying [1 ,2 ]
Zhou, Yi-Dong [1 ,2 ]
Yao, Ru [1 ,2 ]
Wu, Huan-Wen [2 ,3 ]
Zhu, Qing-Li [2 ,4 ]
Wang, Chang-Jun [1 ,2 ]
Mao, Feng [1 ,2 ]
Lin, Yan [1 ,2 ]
Shen, Song-Jie [1 ,2 ]
Sun, Qiang [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Breast Surg, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ultrasound, Beijing, Peoples R China
来源
CANCER MEDICINE | 2019年 / 8卷 / 06期
关键词
bilateral breast cancer; metachronous; survival; synchronous; unilateral; SURVIVAL; OUTCOMES;
D O I
10.1002/cam4.2198
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The incidence of bilateral breast cancer (BBC) is increasing nowadays comprising 2%-11% of all breast cancer (BC). According to the interval time between the first and second cancer, BBC could be divided into synchronous (SBBC) and metachronous (MBBC). However, this interval time is quite different across studies. It remains controversial whether the survival of BBC, SBBC, and MBBC is similar or worse compared to that of unilateral breast cancer (UBC), and whether the survival of SBBC is similar or worse compared to MBBC. To better understand the survival of UBC, BBC, SBBC, and MBBC and how the interval time would influence the prognosis of SBBC and MBBC, we performed this meta-analysis on studies from recent 10 years (2008-2018). Methods Databases of PubMed, Embase, and Web of Science were searched for relevant studies within recent 10 years. Hazard ratio (HR) was adopted to evaluate the difference of overall survival (OS) of UBC, BBC, SBBC, and MBBC. HR of OS comparisons were performed between BBC vs UBC, SBBC vs UBC, MBBC vs UBC, and SBBC vs MBBC with 3, 6, 12 months as the interval time, respectively. Results There were 15 studies of 72 302 UBC and 2912 BBC included in the meta-analysis. The summary HR of OS comparison between BBC vs UBC was 1.68 (95% CI: 1.28-2.20), SBBC vs UBC was 2.01 (95% CI: 1.14-3.55), MBBC vs UBC was 3.22 (95% CI: 0.75-13.78). When 3, 6, 12 months were used as the interval time, the summary HR of the OS comparison between of SBBC vs MBBC were 0.64 (95% CI: 0.44-0.94), 1.17 (95% CI: 0.84-1.63) and 1.45 (95% CI: 1.10-1.92), respectively. Conclusion BBC and SBBC showed worse prognosis in terms of OS compared to UBC while MBBC manifested similar or non-superior survival as UBC. The OS comparison between SBBC and MBBC changed with different interval time used. The longer the interval time used, the worse the survival of SBBC. SBBC with interval of 3-12 months between the two cancers had the worst prognosis. When 6 months was used to differentiate SBBC from MBBC, these two clinical entities showed similar OS.
引用
收藏
页码:2908 / 2918
页数:11
相关论文
共 40 条
  • [1] Clinicopathological Features in Bilateral Breast Cancer
    Baykara, Meltem
    Ozturk, Selcuk Cemil
    Buyukberber, Suleyman
    Helvaci, Kaan
    Ozdemir, Nuriye
    Alkis, Necati
    Berk, Veli
    Koca, Dogan
    Coskun, Ugur
    Oksuzoglu, Berna
    Uncu, Dogan
    Arpaci, Erkan
    Ustaalioglu, Basak Oven
    Demirci, Umut
    Kucukoner, Mehmet
    Dogu, Gamze Gokoz
    Alici, Suleyman
    Akman, Tulay
    Ozkan, Metin
    Aslan, Ulku Yalcintas
    Durnali, Ayse Gok
    Benekli, Mustafa
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4571 - 4575
  • [2] Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort
    Beckmann, K. R.
    Buckingham, J.
    Craft, P.
    Dahlstrom, J. E.
    Zhang, Y.
    Roder, D.
    Stuart-Harris, R.
    [J]. BREAST, 2011, 20 (02) : 158 - 164
  • [3] Contralateral breast cancers: Independent cancers or metastases?
    Begg, Colin B.
    Ostrovnaya, Irina
    Geyer, Felipe C.
    Papanastasiou, Anastasios D.
    Ng, Charlotte K. Y.
    Sakr, Rita A.
    Bernstein, Jonine L.
    Burke, Kathleen A.
    King, Tari A.
    Piscuoglio, Salvatore
    Mauguen, Audrey
    Orlow, Irene
    Weigelt, Britta
    Seshan, Venkatraman E.
    Morrow, Monica
    Reis-Filho, Jorge S.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (02) : 347 - 356
  • [4] Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience
    Diaz, Robert
    Munarriz, Blanca
    Santaballa, Ana
    Palomar, Laura
    Montalar, Joaquin
    [J]. MEDICAL ONCOLOGY, 2012, 29 (01) : 16 - 24
  • [5] Fountzilas E, 2016, AM J CANCER RES, V6, P2611
  • [6] Fritz A., 1998, The SEER Program Code Manual, V3rd
  • [7] Gollamudi SV, 1997, CANCER-AM CANCER SOC, V79, P1362, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO
  • [8] 2-Y
  • [9] Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Graeser, Monika K.
    Engel, Christoph
    Rhiem, Kerstin
    Gadzicki, Dorothea
    Bick, Ulrich
    Kast, Karin
    Froster, Ursula G.
    Schlehe, Bettina
    Bechtold, Astrid
    Arnold, Norbert
    Preisler-Adams, Sabine
    Nestle-Kraemling, Carolin
    Zaino, Mohammad
    Loeffler, Markus
    Kiechle, Marion
    Meindl, Alfons
    Varga, Dominic
    Schmutzler, Rita K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5887 - 5892
  • [10] Incidence and prognosis of synchronous and Metachronous bilateral breast cancer
    Hartman, Mikael
    Czene, Kamila
    Reilly, Marie
    Adolfsson, Jan
    Bergh, Jonas
    Adami, Hans-Olov
    Dickman, Paul W.
    Hall, Per
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4210 - 4216